GLMD
Income statement / Annual
Last year (2023), Galmed Pharmaceuticals Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Galmed Pharmaceuticals Ltd.'s net income was -$6.91 M.
See Galmed Pharmaceuticals Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.04 M |
$1.09 M |
$467,000.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$31,000.00
|
$35,000.00
|
$42,000.00
|
$39,000.00
|
$35,000.00
|
$0.00
|
$0.00
|
$0.00
|
$50,000.00
|
$0.00
|
| Gross Profit |
-$31,000.00
|
-$35,000.00
|
-$42,000.00
|
-$39,000.00
|
-$35,000.00
|
$2.04 M
|
$1.09 M
|
$467,000.00
|
-$50,000.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
| Research and Development Expenses |
$3.57 M
|
$13.00 M
|
$27.22 M
|
$26.08 M
|
$18.18 M
|
$8.31 M
|
$9.65 M
|
$14.27 M
|
$7.63 M
|
$6.66 M
|
| General & Administrative Expenses |
$3.72 M
|
$4.66 M
|
$5.66 M
|
$4.13 M
|
$4.20 M
|
$4.44 M
|
$3.80 M
|
$3.08 M
|
$3.25 M
|
$2.48 M
|
| Selling & Marketing Expenses |
$200,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.92 M
|
$4.66 M
|
$5.66 M
|
$4.13 M
|
$4.20 M
|
$4.44 M
|
$3.80 M
|
$3.08 M
|
$3.25 M
|
$2.48 M
|
| Other Expenses |
-$14.98 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
-$7.49 M
|
$17.65 M
|
$32.88 M
|
$30.21 M
|
$22.38 M
|
$12.75 M
|
$13.45 M
|
$17.35 M
|
$10.88 M
|
$9.14 M
|
| Cost And Expenses |
-$7.49 M
|
$17.65 M
|
$32.88 M
|
$30.21 M
|
$22.38 M
|
$12.75 M
|
$13.45 M
|
$17.35 M
|
$10.88 M
|
$9.14 M
|
| Interest Income |
$375,000.00
|
$297,000.00
|
$562,000.00
|
$1.19 M
|
$1.92 M
|
$959,000.00
|
$65,000.00
|
$35,000.00
|
$253,000.00
|
$40,000.00
|
| Interest Expense |
$11,000.00
|
$215,000.00
|
$43,000.00
|
$31,000.00
|
$33,000.00
|
$42,000.00
|
$49,000.00
|
$67,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$31,000.00
|
$35,000.00
|
$42,000.00
|
$39,000.00
|
$35,000.00
|
$387,000.00
|
$239,000.00
|
$169,000.00
|
$50,000.00
|
$9,000.00
|
| EBITDA |
-$6.87 M |
-$17.62 M |
-$32.84 M |
-$30.17 M |
-$22.34 M |
-$10.33 M |
-$12.13 M |
-$16.71 M |
-$10.83 M |
-$9.13 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-5.08
|
-11.18
|
-35.79
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-5.26
|
-11.4
|
-36.15
|
0
|
0
|
| Total Other Income/Expenses Net |
-$14.40 M
|
-$215,000.00
|
$414,000.00
|
$1.44 M
|
$1.92 M
|
$934,000.00
|
$65,000.00
|
$35,000.00
|
$253,000.00
|
$40,000.00
|
| Income Before Tax |
-$6.91 M
|
-$17.87 M
|
-$32.47 M
|
-$28.77 M
|
-$20.46 M
|
-$9.78 M
|
-$12.30 M
|
-$16.85 M
|
-$10.62 M
|
-$9.10 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-4.8
|
-11.34
|
-36.07
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$705,000.00
|
-$519,000.00
|
-$1.16 M
|
-$1.92 M
|
$75,000.00
|
$12.36 M
|
$106,000.00
|
$21.24 M
|
$1,000.00
|
| Net Income |
-$6.91 M
|
-$18.57 M
|
-$31.95 M
|
-$27.61 M
|
-$18.54 M
|
-$9.86 M
|
-$12.30 M
|
-$16.95 M
|
-$10.62 M
|
-$9.10 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-4.84
|
-11.34
|
-36.3
|
0
|
0
|
| EPS |
-30.05 |
-11.08 |
-19.48 |
-19.46 |
-13.17 |
-8.15 |
-14.77 |
-22.36 |
-14.35 |
-13.23 |
| EPS Diluted |
-29.95 |
-11.08 |
-19.48 |
-19.46 |
-13.17 |
-8.15 |
-14.77 |
-22.36 |
-14.35 |
-13.23 |
| Weighted Average Shares Out |
$230,000.00
|
$1.68 M
|
$1.64 M
|
$1.42 M
|
$1.41 M
|
$1.21 M
|
$832,489.00
|
$758,310.00
|
$740,030.00
|
$688,245.00
|
| Weighted Average Shares Out Diluted |
$230,794.00
|
$1.68 M
|
$1.64 M
|
$1.42 M
|
$1.41 M
|
$1.21 M
|
$832,489.00
|
$758,310.00
|
$740,030.00
|
$688,245.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
